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Rituximab (RTX) is an effective B depleting agent for inducing and maintaining remission in patients with 
Granulomatosis with polyangiitis (GPA). RTX induced late onset neutropenia and hypogammaglobulinemia 
potentiates the risk of common infections, but infections mediated by T-cell dysfunction have also been 
described during RTX treatment. 
 
Objective  
To describe the course of CD4 cells and CD4/CD8 ratio in GPA patients during long term RTX treatment. 
       
Methods 
Analysis of prospectively collected data in 35 GPA patients treated with RTX between April 2004 and 
September 2011 at one centre. Total immunoglobulin (Ig) levels and immunophenotyping of lymphocytes were 
measured at RTX initiation and then after 3, 6, 12, 18 and 24 months.  CD4 < 0.3 x 109/L and CD4/CD8 ratio < 1 
were defined as low count and ratio. Patients (median age 50 (14-79), 46 % women) had received a cumulative 
dose cyclophosphamide of 14.8 g (0-250) were treated with a median RTX cumulative dose of 4 g (2-6). Results 




The CD4 cell count decreased from 0.46 at baseline to respectively 0.38 (p=0.331), 0.41 (p=0.183) x 109/L at 3 
and 6 months and afterwards increased to 0.57 (p=0.034) at 24 months. Ratio decreased from 1.31 to 0.99 
(p=0.007) at 3 months and increased gradually to 1.62 (p=0.057) at 24 months. The proportion of patients with 
low CD4 decreased from 43 % at baseline to 18 % at 24 months while the proportion of patients with low ratio 
remained stable between 34 and 50 % (at 3 months) throughout the study period. 
Patients with low CD4 at baseline had an increase in their CD4 cell count at 3 months (0.18 vs -0.28 x 109/L; 
p=0.003) while patients with normal CD4 cell count had a decrease. Consequently there were no statistical 
difference in CD4 cell count between the 2 groups at 3 months (0.36 vs 0.40 x 109/L; p=0.064).  
Patients with low CD4 at baseline did not have lower level in total Ig throughout RTX maintenance, whereas 
patients with low ratio at baseline had (Table). 
Two patients had severe infections in the first 24 months of RTX maintenance and 1 had an infection due to T-
cell dysfunction (Pneumocystis jiroveci) 4 months after RTX initiation.  
 
Conclusion 
RTX treatment in GPA patients results in a temporary decrease in CD4 cell count and CD4/CD8 ratio for about 
six months. Patients with low baseline ratio remain low during RTX maintenance and are prone to lower Ig 




Patients at baseline Total immunoglobulin level g/L 
Baseline 12 mo 24 mo 
Low CD4 10.8 8.0 7.4 
Normal CD4 11.8 9.2 8.3 
p-value 0.283 0.158 0.179 
Low ratio 11.8 7.6 7.1 
Normal ratio 11.2 9.3 8.4 
p-value 0.461 0.021 0.063 
 
